Nepafenac in cataract surgery

References

• Lee CM, Afshari NA. The global state of cataract blindness. Curr Opin Ophthalmol. 2017;28:98–103.
   PubMed Web of Science ®Google Scholar
• Mylona I, Tsinopoulos I. A critical appraisal of new developments in intraocular lens modifications and drug delivery systems for the prevention of cataract surgery complications. Pharmaceuticals. 2020;13:448.
   Web of Science ®Google Scholar
• Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550–1558.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xia S, Wang E, et al. Comparison of the efficacy and patients’ tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: a meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0173254.
   PubMed Web of Science ®Google Scholar
• McCafferty S, Harris A, Kew C, et al. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol. 2017;17:16.
   PubMed Web of Science ®Google Scholar
• Duan P, Liu Y, Li J. The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2017;255:639–649.
   PubMed Web of Science ®Google Scholar
• Sheppard JD. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clin Ophthalmol. 2016;10:2099–2111.
   PubMed Web of Science ®Google Scholar
• Wolf EJ, Braunstein A, Shih C, et al. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33:1546–1549.
   PubMed Web of Science ®Google Scholar
• Cervantes-Coste G, Sánchez-Castro YG, Orozco-Carroll M, et al. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219–226.
   PubMedGoogle Scholar
• Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1–11.
   PubMedGoogle Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89–98.
   PubMed Web of Science ®Google Scholar
• Chastain JE, Sanders ME, Curtis MA, et al. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016;145:58–67.
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144:146–147.
   PubMed Web of Science ®Google Scholar
• Sarfraz MH, Haq RI, Mehboob MA. Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Pak J Med Sci. 2017;33:210–214.
   PubMed Web of Science ®Google Scholar
• Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40:203–211.
   PubMed Web of Science ®Google Scholar
• Simone JN, Whitacre MM. Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol. 2001;12:63–67.
   PubMed Web of Science ®Google Scholar
• Cagini C, Cerquaglia A, Pellegrino A, et al. Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects. Acta Ophthalmol. 2021;99:e70–e73.
   PubMed Web of Science ®Google Scholar
• Lane SS, Modi SS, Lehmann RP, et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33:53–58.
   PubMed Web of Science ®Google Scholar
• Maxwell WA, Reiser HJ, Stewart RH, et al. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. J Ocul Pharmacol Ther. 2008;24:593–599.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Holland EJ, Solomon KD. Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation following cataract surgery. J Cataract Refract Surg. in press. DOI:10.1097/j.jcrs.0000000000000414
   Google Scholar
• Ogurel T, Ogurel R, Ozkal F, et al. Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection. Ther Adv Ophthalmol. in press. DOI:10.1177/2515841419861856
   Web of Science ®Google Scholar
• Numaga J, Yata K, Miyake S, et al. Phase III open-label study of nepafenac ophthalmic suspension 0.1% for inflammation and ocular pain following ophthalmic surgery. Nippon Ganka Gakkai Zasshi. 2012;116:86–94.
   PubMedGoogle Scholar
• Shields MK, Adler PA, Fuzzard DR, et al. A Case of Acute Bilateral Irvine-Gass Syndrome following Uncomplicated Phacoemulsification, Demonstrated with Optical Coherence Tomography. Case Rep Ophthalmol. 2015;6:143–148.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Isaac DL, Ávila MP. Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. Arq Bras Oftalmol. 2016;79:113–115.
   PubMed Web of Science ®Google Scholar
• Powe NR, Schein OD, Gieser SC, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol. 1994;112:239–252.
   PubMed Web of Science ®Google Scholar
• Jaycock P, Johnston RL, Taylor H, et al. The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. Eye. 2009;23:38–49.
   PubMed Web of Science ®Google Scholar
• Greenberg PB, Tseng VL, Wu WC, et al. Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans. Ophthalmology. 2011;118:507–514.
   PubMed Web of Science ®Google Scholar
• Clark A, Morlet N, Ng JQ, et al. Whole population trends in complications of cataract surgery over 22 years in Western Australia. Ophthalmology. 2011;118:1055–1061.
   PubMed Web of Science ®Google Scholar
• Packer M, Lowe J, Fine H. Incidence of acute postoperative cystoid macular edema in clinical practice. J Cataract Refract Surg. 2012;38:2108–2111.
   PubMed Web of Science ®Google Scholar
• Chaudhary C, Bahadhur H, Gupta N. Study of cystoid macular edema by optical coherent tomography following uneventful cataract surgery. Int Ophthalmol. 2015;35:685–691.
   PubMed Web of Science ®Google Scholar
• Bélair ML, Kim SJ, Thorne JE, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009;148:128–135.
   PubMed Web of Science ®Google Scholar
• Schaub F, Adler W, Enders P, et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2018;256:909–917.
   PubMed Web of Science ®Google Scholar
• Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Surv Ophthalmol. 2004;49:470–490.
   PubMed Web of Science ®Google Scholar
• Giarmoukakis AK, Blazaki SV, Bontzos GC, et al. Efficacy of Topical Nepafenac 0.3% in the management of postoperative cystoid macular edema. Ther Clin Risk Manag. 2020;16:1067–1074.
   PubMed Web of Science ®Google Scholar
• Tzelikis PF, Vieira M, Hida WT, et al. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study. Br J Ophthalmol. 2015;99:654–658.
   PubMed Web of Science ®Google Scholar
• Almeida DR, Khan Z, Xing L, et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J Cataract Refract Surg. 2012;38:1537–1543.
   PubMed Web of Science ®Google Scholar
• Şahin AK, AŞ Kükner, Ulaş F, et al. Effect of nepafenac 0.1% on retinal thickness after cataract surgery in patients without risk factors for cystoid macular edema. Int J Ophthalmol. 2020;13:1901–1907.
   PubMed Web of Science ®Google Scholar
• Mathys KC, Cohen KL. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye. 2010;24:90–96.
   PubMed Web of Science ®Google Scholar
• Tzelikis PF, Morato CS, Neves NT, et al. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification. J Cataract Refract Surg. 2018;44:440–446.
   PubMed Web of Science ®Google Scholar
• Zaczek A, Artzen D, Laurell CG, et al. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. J Cataract Refract Surg. 2014;40:1498–1505.
   PubMed Web of Science ®Google Scholar
• Ilveskoski L, Taipale C, Tuuminen R. Anti-inflammatory medication of cataract surgery in pseudoexfoliation syndrome - NSAID is needed. Curr Eye Res. 2020;45:814–819.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Igarashi C, Hirata A, et al. Changes in diabetic macular oedema after phacoemulsification surgery. Eye. 2009;23:389–396.
   PubMed Web of Science ®Google Scholar
• Mokbel T, Saleh S, Abdelkader M, et al. Functional and anatomical evaluation of the effect of nepafenac in prevention of macular edema after phacoemulsification in diabetic patients. Int J Ophthalmol. 2019;12:387–392.
   PubMed Web of Science ®Google Scholar
• Singh RP, Staurenghi G, Pollack A, et al. Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies. Clin Ophthalmol. 2017;11:1021–1029.
   PubMed Web of Science ®Google Scholar
• Alnagdy AA, Abouelkheir HY, El-Khouly SE, et al. Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. Int J Ophthalmol. 2018;11:616–622.
   PubMed Web of Science ®Google Scholar
• Pollack A, Staurenghi G, Sager D, et al. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2017;101:423–427.
   PubMed Web of Science ®Google Scholar
• Danni R, Viljanen A, Aaronson A, et al. Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac. Acta Ophthalmol. 2019;97:589–595.
   PubMed Web of Science ®Google Scholar
• El Gharbawy SA, Darwish EA, Abu Eleinen KG, et al. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes. Eur J Ophthalmol. 2019;29:453–457.
   PubMed Web of Science ®Google Scholar
• Guzek JP, Holm M, Cotter JB, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology. 1987;94:461–466.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mondal KK, Roy SS, et al. Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: a randomized, double-blind study. Indian J Pharmacol. 2015;47:491–495.
   PubMed Web of Science ®Google Scholar
• Zanetti FR, Fulco EA, Chaves FR, et al. Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. Indian J Ophthalmol. 2012;60:277–281.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Baskaran P, Talwar B, et al. Prospective, randomized study comparing the effect of 0.1% Nepafenac and 0.4% ketorolac tromethamine on macular thickness in cataract surgery patients with low risk for cystoid macular edema. Asia Pac J Ophthalmol. 2015;4:216–220.
   PubMed Web of Science ®Google Scholar
• Hoffman RS, Braga-Mele R, Donaldson K, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2016;42:1368–1379.
   PubMed Web of Science ®Google Scholar
• Kawahara A, Utsunomiya T, Kato Y, et al. Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial. Clin Ophthalmol. 2016;10:385–391.
   PubMed Web of Science ®Google Scholar
• Jones BM, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother. 2013;47:892–896.
   PubMed Web of Science ®Google Scholar
• Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371–384.
   PubMed Web of Science ®Google Scholar
• Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281–291.
   PubMed Web of Science ®Google Scholar
• Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: i. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24:357–370.
   PubMed Web of Science ®Google Scholar
• Hovanesian J, Holland E. Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5. J Cataract Refract Surg. 2019;45:174–180.
   PubMed Web of Science ®Google Scholar
• Nardi M, Lobo C, Bereczki A, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. Clin Ophthalmol. 2007;1:527–533.
   PubMedGoogle Scholar
• Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539–1545.
   PubMed Web of Science ®Google Scholar
• Toyos MM. Comparison of once-daily bromfenac 0.07% versus once-daily nepafenac 0.3% in patients undergoing phacoemulsification. Ophthalmol Ther. 2019;8:261–270.
   PubMed Web of Science ®Google Scholar
• Duong HV, Westfield KC, Chalkley TH. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007;33:1925–1929.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Schoenberger SD, Thorne JE, et al. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American academy of ophthalmology. Ophthalmology. 2015;122:2159–2168.
   PubMed Web of Science ®Google Scholar
• Sahu S, Ram J, Bansal R, et al. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification. J Cataract Refract Surg. 2015;41:2043–2048.
   PubMed Web of Science ®Google Scholar
• Cagini C, Pellegrino A, Cerquaglia A, et al. Comparison of the effect of diclofenac 0.1% and nepafenac 0.1% on aqueous flare in patients undergoing cataract surgery: a prospective randomized study. Curr Eye Res. 2020;45:1089–1093.
   PubMed Web of Science ®Google Scholar